- 7 hrs ago A 12-Year-Old Colour-Blind Boy Gets Emotional After He Sees Colours For The First Time
- 10 hrs ago Hina Khan’s Mesmerising Blue Eye Make-up Is All You Need To Slay This Holiday Season
- 11 hrs ago Rasika Dugal's Black Outfit Can Easily Elevate Your Formal Look
- 13 hrs ago Instagram Beauty Trends Of The Week: Deepika Padukone, Ranveer Singh, Kareena Kapoor & More
- Movies Miss World 2019: Miss Jamaica Toni-Ann Singh Wins The Crown; India's Suman Rao Is The 2nd Runner Up!
- Sports West Indies built credibility with T20 performance against India, will be a force to reckon with during WC: Brian Lara
- Technology Micromax Revenue From Sales Fall 45% To Rs. 2,368.79 Crore In FY19: Report
- News CAB protest: Violence in WB; curfew relaxed in parts of Assam, Meghalaya
- Automobiles Volvo XC40 T4 R-Design Petrol Launched In India At Rs 39.90 Lakh, Ex-Showroom
- Finance RBI To Offer Liquidity Support Scheme For 24X7 Functionality Of Neft
- Travel How Christmas Is Celebrated In Different Parts Of India
- Education AIIMS BSc Nursing 2020 Registration Process Started
A vaginal ring that contains an experimental antiretroviral (ARV) drug, previously found to provide protection against HIV infection in women, has been found safe and acceptable in teenage girls, researchers claim.
Dapivirine, also known as TMC-120, belongs to a class of ARVs called non-nucleoside reverse transcriptase inhibitors that bind to and disable HIV's reverse transcriptase enzyme -- a key protein needed for HIV replication.
The dapivirine ring, made of a flexible material, has already been shown to be both safe and to help protect against HIV among women aged 18-45 years in earlier clinical trials.
However, the new study found the ring safe to use by girls aged under 18.
"If the ring is approved for women older than age 18, it's imperative that we have the data in hand to show that the ring is safe to use in younger women as well," said lead investigator Sharon Hillier, Professor at the University of Pittsburgh in Pennsylvania, US.
"HIV doesn't distinguish between a 16-year-old and an 18-year-old. Access to safe and effective HIV prevention shouldn't either. Young women of all ages deserve to be protected," Hillier added while presenting the findings at the 9th IAS Conference on HIV Science 2017 in Paris.
For the new study, known as MTN-023/IPM 030, the team enrolled 96 girls aged 15-17. Participants were randomly assigned to use either the dapivirine ring (73) or a placebo ring (23) for a month at a time for a total of six months.
The study found no differences in safety outcomes between the dapivirine ring and the placebo ring, the researchers noted.
Adherence to ring use was also high. By self-report, 42 per cent of participants said they had never removed the ring except to replace it monthly.
While 95 per cent said that the ring was easy to use, 74 per cent indicated they were not aware of the ring during daily activities.
The study provides information about safety and tolerability that regulatory authorities would need to expand approval of the ring to also include girls under the age of 18, the researchers noted.
With Inputs From IANS